- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01362764
A Study to Assess the Relative Bioavailability of Two Abiraterone Acetate Suspension Formulations Compared to the Abiraterone Acetate Tablet Formulation in Healthy Adult Volunteers
November 26, 2012 updated by: Cougar Biotechnology, Inc.
A Single-Dose, Open-Label, Randomized, Crossover Study to Assess the Relative Bioavailability of Two Abiraterone Acetate Suspension Formulations Compared to the Abiraterone Acetate Tablet Formulation Under Fasted Condition in Healthy Adult Subjects
The purpose of this study is to compare the single-dose pharmacokinetics (how the drug is absorbed in the body, distributed within the body, and how it is removed from the body) of the solution formulation to the tablet formulation; therefore the lowest dose available in the tablet formulation (250 mg) was selected.
Study Overview
Status
Completed
Conditions
Detailed Description
This is an open-label (volunteer and study staff will know the identity of the assigned treatment) study of two abiraterone acetate suspension formulations, compared to the abiraterone acetate tablet formulation in healthy volunteers.
Approximately 30 healthy volunteers will participate in this study.
Each volunteer will be randomly assigned to 1 of 6 possible treatment sequences.
The study consists of a screening phase (within 21 days before the first study drug administration of the first period); an open-label treatment phase consisting of 3 single dose treatment periods; and end-of-study or withdrawal assessments done upon completion of the 72-hour (Day 4 of Period 3, or upon withdrawal) sampling to evaluate how the drug is absorbed in the body, distributed within the body, and how it is removed from the body over time.
A 7- to 14-day washout period will separate the study drug administrations.
The duration of participation in the study for an individual healthy volunteer will be from 41 days to a maximum of 55 days (including screening).
Safety will be monitored.
Volunteers will receive a 250 mg dose of abiraterone acetate as a tablet, suspension Formulation 1, and suspension Formulation 2 according to their treatment sequence.
Abiraterone acetate tablets must be swallowed whole and not chewed, divided, dissolved or crushed and will be taken with 240 mL of noncarbonated water.
For the suspensions, the volunteer will drink the contents of the vial.
The vial will be rinsed with 10 mL of water, and the volunteer will be asked to drink the rinse water.
Study Type
Interventional
Enrollment (Actual)
30
Phase
- Phase 1
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 55 years (Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- Having signed an informed consent document
- Agreeing to use an adequate contraception method, as deemed appropriate by the investigator (e.g., vasectomy, double-barrier, partner using effective contraception) and to not donate sperm during the study and for 3 months after receiving the last dose of study drug
- Body mass index (weight [kg]/height2 [m]2) between 18 and 30 kg/m2 (inclusive), and body weight not less than 50 kg
- Blood pressure (after the volunteer is sitting for 5 minutes) between 90 and 140 mm Hg systolic, inclusive, and no higher than 90 mm Hg diastolic during screening Days -21 to Day -1
- Having a 12-lead electrocardiogram (ECG) consistent with normal cardiac conduction and function
- Morphology consistent with healthy cardiac conduction and function
Exclusion Criteria:
- History of or current clinically significant medical illness including (but not limited to) cardiac arrhythmias or other cardiac disease, hematologic disease, coagulation disorders (including any abnormal bleeding or blood dyscrasias), lipid abnormalities, significant pulmonary disease, including bronchospastic respiratory disease, diabetes mellitus, renal or hepatic insufficiency, thyroid disease, neurologic or psychiatric disease, infection, or any other illness that the investigator considers should exclude the volunteer or that could interfere with the interpretation of the study results
- Clinically significant abnormal values for hematology, clinical chemistry or urinalysis at screening or at admission to the study center as deemed appropriate by the investigator
- Clinically significant abnormal physical examination, vital signs or 12-lead ECG at screening or at admission to the study center as deemed appropriate by the investigator
- Use of any prescription or nonprescription medication (including vitamins and herbal supplements), except for acetaminophen, within 14 days before the first dose of the study drug is scheduled
- History of, or a reason to believe a volunteer has a history of drug or alcohol abuse within the past 2 years
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: 001
Abiraterone acetate tablets Type=exact unit=mg number= 250 form=tablet route=oral use as a single dose
|
Type=exact, unit=mg, number= 250, form=tablet, route=oral use, as a single dose
|
Other: 002
Abiraterone acetate suspension Formulation 1 Type=exact unit=mg/mL number=25 form=oral suspension route=oral use as a single dose of 10 mL
|
Type=exact, unit=mg/mL, number=25, form=oral suspension, route=oral use, as a single dose of 10 mL
|
Other: 003
Abiraterone acetate suspension Formulation 2 Type=exact unit=mg/mL number=25 form=oral suspension route=oral use as a single dose of 10 mL
|
Type=exact, unit=mg/mL, number=25, form=oral suspension, route=oral use, as a single dose of 10 mL
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Levels of study drug
Time Frame: Up to 55 days
|
Up to 55 days
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Vital signs evaluations
Time Frame: Up to 55 days
|
Up to 55 days
|
Adverse events
Time Frame: Up to 55 days
|
Up to 55 days
|
Clinical laboratory findings, based on blood and urine tests
Time Frame: Up to 55 days
|
Up to 55 days
|
Physical examination evaluations
Time Frame: Up to 55 days
|
Up to 55 days
|
Electrocardiogram changes
Time Frame: Up to 55 days
|
Up to 55 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
May 1, 2011
Primary Completion (Actual)
June 1, 2011
Study Completion (Actual)
June 1, 2011
Study Registration Dates
First Submitted
May 27, 2011
First Submitted That Met QC Criteria
May 27, 2011
First Posted (Estimate)
May 30, 2011
Study Record Updates
Last Update Posted (Estimate)
November 27, 2012
Last Update Submitted That Met QC Criteria
November 26, 2012
Last Verified
November 1, 2012
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CR018067
- 212082HPL1001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy Volunteers
-
AstraZenecaCompletedHealthy Elderly Volunteers | Healthy Young VolunteersUnited States
-
Syndax PharmaceuticalsCompletedHealthy Volunteers | Volunteers | Normal Volunteers | Human VolunteersUnited States
-
Syndax PharmaceuticalsCompletedHealthy Volunteers | Volunteers | Normal Volunteers | Human VolunteersUnited States
-
University Hospital, Clermont-FerrandUnite de Nutrition Humaine UMR 1019- INRAE; Unite MetaGenoPolis INRAE; France...CompletedHealthy Volunteers | Frail VolunteersFrance
-
Galera Therapeutics, Inc.CelerionCompletedHealthy | Healthy VolunteersUnited States
-
Newcastle UniversityCompletedGI Glycaemic Index Healthy Volunteers | GL Glycaemic Load Healthy VolunteersUnited Kingdom
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
PMV Pharmaceuticals, IncRecruitingHealthy VolunteersUnited States
Clinical Trials on Abiraterone acetate tablets
-
Jiangsu HengRui Medicine Co., Ltd.Not yet recruitingHigh-volume, Metastatic, Hormone-sensitive Prostate Cancer (mHSPC)
-
The Affiliated Hospital of Qingdao UniversityCompletedHealthy VolunteersChina
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Terminated
-
Zhongnan HospitalActive, not recruitingPharmacokinetic | Abiraterone Acetate | Plasma Concentration | Gene Polymorphism | Metabolic AnalysisChina
-
Janssen Research & Development, LLCCompleted
-
Cougar Biotechnology, Inc.Completed
-
Jiangsu HengRui Medicine Co., Ltd.CompletedMetastatic Castration-resistant Prostate Cancer (mCRPC)China
-
Cougar Biotechnology, Inc.CompletedProstate NeoplasmsUnited Kingdom, United States
-
Janssen Research & Development, LLCCompletedHealthy ParticipantsUnited States
-
Assistance Publique - Hôpitaux de ParisJanssen, LPCompletedProstate CancerFrance